Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.
The case for DSHEA reform
In this episode of “short legal briefs” with host Josh Long, a professor at Harvard Medical School whose research has identified drugs in “dietary supplements,” joins a former FDA official who leads an advocacy group in the nation’s capital to discuss the need for reform of the Dietary Supplement Health and Education Act of 1994 (DSHEA).
September 30, 2021
1 Min Read
Peer-reviewed research published this month disclosed a substance prescribed in Russia as a drug was being marketed in dietary supplements in the U.S. even after FDA issued an advisory in 2019 clarifying phenibut was not a legal supplement ingredient.
Dr. Pieter Cohen, an associate professor of medicine with Harvard Medical School, highlights researchers’ findings, while the president of the Center for Science in the Public Interest (CSPI), Dr. Peter Lurie, weighs in on his advocacy group’s investigation that separately found several retailers marketing phenibut in supplements, foods or other products.
Drs. Cohen and Lurie also offer reasons for their support of reform of DSHEA, including an FDA proposal that would require dietary supplement products be listed with the agency.
Discussing the notion of DSHEA reform, Cohen concluded: “There’s a lot of opportunity to collaborate on this, and it remains an exciting time for us to come to some great solutions that can enhance the safety of supplements for all consumers.”
You May Also Like